| Characteristic | Total group (n = 36) | Placebo (n = 18) | Memantine (n = 18) |
| Age, years | 76.2 (5.21) | 75.8 (5.70) | 76.5 (4.81) |
| Sex, female | 23.0 (63.9) | 10.0 (55.6) | 13.0 (72.2) |
| Apolipoprotein-E-4 allele | 16.0 (44.4) | 8.0 (44.4) | 8.0 (44.4) |
| Hachinski score | 1.1 (1.27) | 0.8 (0.99) | 1.4 (1.46) |
| MMSE | 19.0 (2.90) | 19.3 (2.72) | 18.7 (3.12) |
| GDS | 2.4 (0.94) | 2.2 (1.00) | 2.6 (0.85) |
| CDR | 1.6 (0.56) | 1.5 (0.51) | 1.6 (0.61) |
| ADAS-Cog | 27.5 (10.59) | 27.5 (10.00) | 27.6 (11.45) |
| Normalised brain volume, ml | 1298.3 (76.5) | 1311.4 (77.5) | 1285.9 (75.8) |
All data are expressed as mean and standard deviation (SD) except for sex and APO-E-4 allele, which are expressed as frequency and percentage.
ADAS-Cog, Alzheimer Disease Assessment Scale – cognitive subscale; CDR, Clinical Dementia Rating; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination.